Given the encouraging data from the in vitro and in vivo experiments, we conducted a phase I, single-center, open-label clinical trial (ChiCTR1800016584) to evaluate the feasibility, safety, and clinical and biologic activity of manufacturing and administering CD19-targeted KIRS2/Dap12-BB and BBζ CAR-T cells to adult patients with r/r B-ALL. Here, CD19 is linked to acute lymphoblastic leukemia.